Medtronic jumps after Q4 results beat expectations and FY27 outlook comes in strong

Medtronic plc (MDT) is up 5.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to Medtronic’s fiscal Q4 and full-year FY2026 earnings release, which showed stronger-than-expected revenue and adjusted EPS relative to its implied guidance. Investors also seemed to react positively to the company’s upbeat FY2027 organic growth and non-GAAP EPS outlook, alongside a dividend increase.

Details:

Quarterly revenue was $9.807 billion, up 9.9% reported (6.6% organic), with non-GAAP diluted EPS of $1.55 (GAAP diluted EPS of $0.96).

Cardiac Ablation Solutions was a notable growth driver, with revenue up 78% globally (including 124% in the U.S.), while the broader Cardiovascular portfolio grew 10.1% organically in the quarter.

Full-year FY2027 guidance called for 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00.

Management approved a higher quarterly dividend of $0.72 per share for Q1 FY2027 (annualized $2.88), payable July 17, 2026, to holders of record June 26, 2026.

Sources:

U.S. Securities and Exchange Commission, Medtronic Newsroom, PR Newswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDT Insider Trading Activity

$MDT insiders have traded $MDT stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $MDT stock by insiders over the last 6 months:

HARRY SKIP KIIL (EVP & President Cardiovascular) has made 0 purchases and 5 sales selling 52,524 shares for an estimated $5,132,217.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MDT Hedge Fund Activity

We have seen 1,063 institutional investors add shares of $MDT stock to their portfolio, and 1,170 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WCM INVESTMENT MANAGEMENT, LLC added 11,265,714 shares (+inf%) to their portfolio in Q1 2026, for an estimated $976,174,118
CAPITAL WORLD INVESTORS added 9,471,538 shares (+134.6%) to their portfolio in Q1 2026, for an estimated $820,708,767
BLACKROCK, INC. removed 7,355,311 shares (-6.1%) from their portfolio in Q1 2026, for an estimated $637,337,698
CAPITAL RESEARCH GLOBAL INVESTORS added 7,353,427 shares (+21.3%) to their portfolio in Q1 2026, for an estimated $637,174,449
WELLINGTON MANAGEMENT GROUP LLP removed 5,833,795 shares (-43.7%) from their portfolio in Q1 2026, for an estimated $505,498,336
BOSTON PARTNERS removed 4,707,978 shares (-69.9%) from their portfolio in Q1 2026, for an estimated $407,946,293
CITADEL ADVISORS LLC removed 4,246,447 shares (-81.2%) from their portfolio in Q1 2026, for an estimated $367,954,632

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDT Congressional Stock Trading

Members of Congress have traded $MDT stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MDT stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN sold up to $50,000 on 03/20.
REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MDT Analyst Ratings

Wall Street analysts have issued reports on $MDT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/17/2026
Barclays issued a "Overweight" rating on 01/08/2026
William Blair issued a "Outperform" rating on 01/06/2026

To track analyst ratings and price targets for $MDT, check out Quiver Quantitative's $MDT forecast page.

$MDT Price Targets

Multiple analysts have issued price targets for $MDT recently. We have seen 12 analysts offer price targets for $MDT in the last 6 months, with a median target of $108.0.

Here are some recent targets:

Priya Sachdeva from UBS set a target price of $90.0 on 04/22/2026
Richard Newitter from Truist Securities set a target price of $95.0 on 04/15/2026
Anthony Petrone from Mizuho set a target price of $120.0 on 04/13/2026
Vijay Kumar from Evercore ISI Group set a target price of $106.0 on 04/09/2026
Joanne Wuensch from Citigroup set a target price of $110.0 on 04/07/2026
David Toung from Argus Research set a target price of $115.0 on 04/06/2026
Matt O'Brien from Piper Sandler set a target price of $91.0 on 04/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.